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Toxoplasma gondii is a prevalent obligate intracellular parasite which chronically infectsmore than a third of the world’s population.
Key to parasite prevalence is its ability to form chronic and nonimmunogenic bradyzoite cysts, which typically form in the brain
and muscle cells of infected mammals, including humans. While acute clinical infection typically involves neurological and/or
ocular damage, chronic infection has been more recently linked to behavioral changes. Establishment and maintenance of chronic
infection involves a balance between the host immunity and parasite evasion of the immune response. Here, we outline the known
cellular interplay between Toxoplasma gondii and cells of the central nervous system and review the reported effects of Toxoplasma
gondii on behavior and neurological disease. Finally, we review new technologies which will allow us to more fully understand
host-pathogen interactions.
1. Introduction
Toxoplasma gondii belongs to the phylum Apicomplexa,
which consists of intracellular parasites having a characteris-
tically polarized cell structure and a complex cytoskeletal and
organellar arrangement at their apical end [1]. This obligate
intracellular parasite can infect and replicate within virtually
any nucleated mammalian or avian cell [2, 3]. It is believed
that the major transmissionmethod of T. gondii to humans is
the consumption of raw or rare meat [4–6]. In addition, ver-
tical transmission ofT. gondii is also possible, occurring when
a female receives a primary infection while pregnant which
can lead to fetal morbidity such as hydrocephaly. Indeed, T.
gondii infection is a primary cause of fetal malformations in
the United States [7]. Up to 80% of a population may be
infected, depending on eating habits and exposure to felines,
which serve as the definitive hosts and shed environmentally
robust oocysts in feces [7, 8]. Oocysts can be stable in the
environment for up to a year, may contaminate food or water
supplies, and infect other warm blooded vertebrates [9]. A
recent study suggested that oocyst-acquired infections are the
most clinically severe form of infection, which may occur not
just through direct cat fecal exposure, but contamination of
municipal drinking water [10].
Two critical intracellular stages in the pathogenesis and
transmission of Toxoplasma gondii are the rapidly replicat-
ing tachyzoite stage and the slower growing, cyst-forming
bradyzoite stage. Initially, latent infections in humans were
assumed to be largely asymptomatic. However, during
the initial AIDS crisis, Toxoplasma became known as a
major opportunistic pathogen [11]. As the host adaptive
immune response weakens, parasite tissue cysts rupture and
release bradyzoites through an unknown mechanism. These
recrudescent infections permit parasite conversion to the
rapidly-dividing tachyzoite stage and produce significant
morbidity, including Toxoplasma encephalitis [12, 13].
Until recently, T. gondii chronic infections were con-
sidered largely innocuous in the otherwise healthy patient,
despite observed neurological changes. However, more
recent studies on model animals have suggested that behav-
ioral changes are manifest following infection [14]. More-
over, recent associations have been made between parasite
infection and neurological disorders, such as schizophrenia
[15]. Hence, it is critical that the relationship between both
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host and parasite, and between infection and disease, be
subjected to more analysis. Central to these issues is the
involvement of the host immune response, which is only
beginning to be delineated and understood.
2. Acute Infection and Dissemination
Themost frequent cause of primary infection is the ingestion
of Toxoplasma gondii tissue cysts. Surviving the gastric pro-
cesses, the parasite excysts to cross into intestinal epithelium
and continues propagation [16]. Due to advantageous intra-
cellular localization, the parasite is largely protected from
soluble, humoral, or cellular antimicrobial factors, although
the degree of success may be dependent on the parasite geno-
type [17]. However, a TH1 immune response is nevertheless
triggered during this acute stage, as recently reviewed in [18,
19]. The parasite has developed adaptations which allow it
to manipulate the innate immune system, frequently leading
to continued proliferation in the gut tissue, despite the
influx of lymphocytes and cells of the innate immune system
[20]. Paradoxically, it is believed that these cells, particularly
dendritic cells and macrophages, are intracellularly infected
and grant the parasite the ability to spread hematogenously
via a “Trojan horse” approach [21–23].
Once in circulation, parasites are able to migrate within
infected cells and remain in the tachyzoite state prior to
activation of the adaptive immune response [24]. Thereafter,
parasites somehow become confined to muscle and brain
tissue [25]. In a process poorly understood, the parasites
are believed to traverse the endothelial cells comprising
the blood brain barrier. A recent study by Lachenmaier
et. al suggests that infected murine brain endothelial cells
promote infected leukocyte migration through the blood
brain barrier [26]. Whether other mechanisms, such as
extracellular parasite barrier penetration, are used to gain
access to the CNS is still unknown.
3. Bradyzoite Formation
The chronic, robust bradyzoite stage is critical for the
transmission of the parasite via carnivorism and likely
accounts for parasite ubiquity. Tissue cysts are composed of
host cells whichmay contain 100 ormore individual parasites
surrounded by a cyst wall produced during differentiation.
The transition to the chronic stage is thought to be induced
by exogenous stressors to the parasite, host, or both or may
occur spontaneously depending on infected cell type [27–
30]. According to Blader and Saeij, neurons and muscle
cells are terminally differentiated and withdrawn from the
cell cycle. They have suggested a model in which tachyzoite
growth is favored inside of growing cells, but when tachy-
zoites cannot manipulate the host’s cell cycle, bradyzoite
development initiates [31].
The most physiologically effective method of bradyzoite
stage induction in vitro is increasing the pH of the culture
media to 8.0–8.2, although variations of this method exist
[32, 33]. Exposure of Toxoplasma gondii to an alkaline media
prior to host cell invasion enhances bradyzoite differentiation
[34]. Alternatively, heat shock (43◦C) of the host cells for
2 hours prior to invasion followed by parasite invasion for
2 hours at 37◦C and additional heat shock of infected cells
for 12–48 hours after infection is an induction method
less harsh to host cells [32]. Chemical induction methods,
such as the use of sodium arsenite, sodium nitroprusside,
or a trisubstituted pyrrole (Compound 1), are also effective
[32, 35, 36]. Nutrient deprivation, such as the amino acid
arginine, slows growth and enhances differentiation [27, 37].
Simultaneous inhibition of pyrimidine de novo biosynthesis
and salvage pathways (via low CO2) also induces slow growth
and differentiation to bradyzoites [38]. Alteration of host
cell gene expression has been shown to slow tachyzoites
replication, which may induce bradyzoite specific gene
expression [39]. Thus, application of exogenous stress to the
parasite appears to consistently trigger the formation of the
bradyzoite state in vitro.
Due to the clinical importance of the bradyzoite stage,
and the ability to generate this stage in vitro, it has been the
focus of several studies [12, 27, 33, 40–42]. The T. gondii
cyst wall membrane, largely consisting of glycoproteins,
is thought to be critical in maintaining the structural
and nutrient needs of the parasite while mitigating host
immune system detection [43–45]. Additional observable
changes occur in subcellular organelles, including a decrease
in dense granules, and an increase in micronemes and
large amylopectin granules. The parasite downregulates cell
division and enters a quiescent G0 state [28], and general
protein translation slows considerably due to parasite eIF2
phosphorylation [46, 47]. Interestingly, knocking out an
abundant protease inhibitor in the parasite led to enhanced
bradyzoite formation in vitro [48]. Transcriptional profiles
of high-resolution timecourse experiments of tachyzoites
undergoing differentiation are available at eupathdb.org [49–
51]. These studies include parasite transcript measurements
from multiple strains subjected to a variety of induction
conditions, including CO2 starvation, sodium nitroprusside,
alkaline media, or Compound 1 treatment. Results from
these studies not only confirm the upregulation of known
bradyzoite markers, but also reveal a novel set of early upreg-
ulated transcripts (Davis PH, manuscript in preparation).
According to Sullivan et al., the bradyzoite cyst form
strongly contributes to the success of Toxoplasma in the
following manner [12]: (1) the cyst survives gastrointestinal
processes, allowing invasion of the small intestine; (2) the
cyst is resistant to host immune response (and current drug
treatments); (3) the parasites persist without perturbing host
cells throughout the lifespan of the host; (4) bradyzoites in
tissue cysts are infectious, lending to carnivorous transmis-
sion.
4. Immune Response to CNS Infection
Upon entering tissues of the central nervous system, the
parasite establishes a delicate balance of low metabolic and
proliferative activity, while avoiding robust host immune
system activation [52]. Meanwhile, it is advantageous for
the host to balance prolific replication of the pathogen
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with the potential for intense immunopathology. While
most subclinical infections of Toxoplasma demonstrate this
balance, it should be noted that the interplay between various
host and parasite genotypes allows for considerable variation
in observed immune response and course of infection [53–
57]. Due to the difficulties in studying human CNS infec-
tions, most reported information concerning the immune
response in T. gondii CNS infection originates from murine
models. In recognition of known immunological differences
between mice and humans, cross-species comparisons of
effector molecules can be difficult [58, 59]. However, these
models have yielded substantial understanding of the cellular
immunoregulation of Toxoplasma infection [19]. Several
studies of the effects of Toxoplasma infection on cells of the
CNS have been compiled in Table 1.
Upon entry to the CNS, tachyzoite parasites appear to
infect astrocytes, neurons, and microglial cells, possibly with
different affinities. Parasite infiltration is followed by CD4+
and CD8+ T cell influx in a process still not fully understood,
but which is critical for control of T. gondii CNS infection,
and which can be activated via CD28 or ICOS stimulatory
pathways [60–64]. Infection and subsequent lymphocyte
infiltration is reported to cause structural modifications
to CNS tissues, based on two-photon image observations
[65]. Cellular components of the innate response, such
as macrophages and NK cells, are also able to enter the
CNS during infection, but their role is less clear. A main
feature of influxed activated T cells is the production of
IFN-gamma, shown to be essential for the prevention of
parasite reactivation in an immune cell-mediated manner
[66, 67]. To a lesser degree, microglial and other cells also
generate IFN-gamma, as well as several other pro- and anti-
inflammatory cytokines and chemokines following infection
[68–72]. In vitro work suggests that astrocytes and microglial
cells are able inhibit parasite replication upon activation
[73–75], possibly explaining why neurons are the dominant
chronically infected cell type [76, 77]. Moreover, the process
of parasite clearance appears reliant on host cell autophagy
[78, 79]. However, a recent report suggests that microglial
cells may function as a “Trojan horse” in the dissemination
of recrudescent parasite infection [80].
During and following acute CNS infection by T. gon-
dii, the host must maintain a balance of controlling par-
asite proliferation, while avoiding immunity-induced dam-
age. The inhibitory effect of IL-10 is required to prevent
immunopathology during primary infection, but not re-
quired to prevent immune hyperactivity during secondary
challenge to T. gondii, nor required to generate a memory
response [81]. IL-27 has also been described as immuno-
suppressive in the context of toxoplasmosis and may induce
IL-10 production [82–84]. Immune-related pathology is also
believed to be locally controlled by inducible TIMP-1, an
inhibitor of matrix metalloproteinases (MMPs) produced by
astrocytes and other microglial cells [85]. Upon CNS infec-
tion by the parasite, T cells migrating into the CNS have
shown increased expression of MMP-8 and MMP-10, pro-
teins involved in tissue remodeling, cell migration, and in-
flammation. The absence of the MMP inhibitor TIMP-1 re-
duced parasite load approximately four-fold, but it is pre-
dicted that additional CNS damage would occur in the pre-
sence of untempered MMP activity [86, 87].
Once a chronic infection is established, the parasite is
predominantly found in the bradyzoite stage within the CNS.
Based on microscopic studies, cysts were located through-
out the brain, but concentrated in the cerebral cortex, hippo-
campus, basal ganglia, and amygdala [88]. The cyst stage do-
minance may be due to at least two phenomena: first, the
acute immune response may successfully clear cells infected
with the tachyzoite stage, leaving only bradyzoite-containing
cells to remain viable. Second, the interferon-gamma upreg-
ulation associated with the acute response may maintain
parasite differentiation [27]. Recent studies have shown that,
unlike extracellular parasites, cyst-bearing cells are not visible
to CD8+ T cells, suggesting that such intracellular cyst struc-
tures are an effective means of immune evasion [89]. Alter-
natively, this data may be explained by the relatively low
MHC class I displayed by neurons. Additionally, T cell behav-
ior has been shown to be dependent on antigen availability in
the CNS [65].
Of note, various alterations in the host immune response
have been shown to allow recrudescent disease, hallmarked
by parasite conversion back to tachyzoites and ultimately tox-
oplasmic encephalitis [90]. The clinical relevancy of this find-
ing became apparent during the onsets of the AIDS epidemic
[91]. However, in most immunocompetent conditions, para-
site infections will remain in a chronic subclinical state (aside
from possible behavioral modifications, discussed below) for
the lifespan of the host. Whether bradyzoite cysts regularly
(or randomly) burst open in immunocompetent hosts and
quickly reinvade nearby cells is an unsettled question [13]. It
is possible that infrequent cyst release is met with a robust
memory response which eliminates some or all extracellular
parasites prior to reinvasion. Or the bradyzoite cysts may
simply be capable of outlasting the host. Likely, some com-
bination of these events contributes to the long-lasting ba-
lance demonstrated by the interaction of the host and par-
asite, thus making it one of the most prevalent parasitic
infections globally.
5. Exploring the Effects of
Toxoplasma gondii on Behavior
Certain parasites have been known to selectively alter host
behavior to enhance their transmission. Although latent
infection with Toxoplasma gondii is among the most preva-
lent human infections, it has been assumed to be mostly
asymptomatic, despite early work showing deleterious mem-
ory effects on murine models [92]. More recently, it has
been found that the parasite has the ability to modify host
behavior. Infected rats were shown to be less fearful of
cats (the definitive host of the parasite) as compared to
noninfected controls, thus conferring a sexual advantage
to the parasite [93]. This has lead researchers to speculate
whether the parasite may have similar effects on humans
[14, 94]. It is unknown whether these behavioral changes
in the host are due to the parasite alone, or are they due
to the outcome of the host’s immune response against the
parasite. Alternatively, such effects could be side effects of
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Table 1: The response of CNS-resident cells to Toxoplasma gondii infection.
Brain cell type Parasite stage Activity Reference
Neuron Tachyzoite Parasites can encyst in neurons [75]
Neuron Tachyzoite
Infection induces cytokine and chemokine production; stimulated neurons
are unable to inhibit parasite growth
[121]
Neuron Bradyzoite Neurons containing parasite cysts avoid scrutiny by CD8+ T cells [89]
Neuron, microglia Tachyzoite
Murine Nramp1−/− models are affected in stress response and mortality
following Toxoplasma gondii infection
[122]
Microglia
Tachyzoite,
bradyzoite
Microglial cells are preferentially infected, but most effectively inhibit
parasitic growth within CNS cells
[25]
Microglia Tachyzoite
Upon Toxoplasma infection, microglia produce IL-1 beta, IL-10, and tumor
necrosis factor-alpha
[123]
Microglia, endothelium Tachyzoite
Murine model infection induce an upregulation of CD200R & CD200,
which control CNS inflammation
[124]
Microglia, astrocyte Tachyzoite Infection downregulates MHC class II expression [125]
Microglia Tachyzoite
Toxoplasmic encephalitis induces IL-12p40, iNOS, IL-1beta, TNF-alpha
largely due to CD8+ T cell interaction. MHC classes I and II, ICAM-1, and
leukocyte function-associated antigen-1 are also upregulated
[126]
Endothelium Tachyzoite
Toxoplasmic encephalitis induces vascular cell adhesion molecule, ICAM-1,
and MHC classes I and II. Induction depends on IFN-gamma receptor
[127]
Endothelium Tachyzoite
Infection induces ICAM-1, IL-6, and MCP-1
Induction levels vary depending on parasite strain
[26]
Astrocyte, neuron Tachyzoite Astrocytes are preferentially infected compared to neurons [75]
Astrocyte, microglia Tachyzoite Intracellular infection reduces expressed MHC II [125]
Astrocyte Tachyzoite
Interferon-gamma-activated indoleamine 2,3-dioxygenase (IDO)
induction inhibits parasite growth
[128]
Astrocyte Tachyzoite
IFN- gamma induced parasite growth inhibition is independent on reactive
oxygen intermediates
[129]
Astrocyte
Tachyzoite,
bradyzoite
Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) is induced by infection [85]
Astrocyte Tachyzoite
Autophagy may be involved in the elimination of the degraded parasite
material from the astrocyte host cell cytoplasm
[79]
Astrocyte Tachyzoite IGTP is required for IFN-gamma-induced inhibition of parasite growth [130]
host illness or even a fortuitous byproduct, such as inducing
the host to undertake greater risks to meet higher energy
demands [95, 96]. For example, infected rats are more active
than uninfected counterparts [97]. Intriguingly, infected rats
are less neophobic (fear of novelty) to each novel stimuli
presented, as compared to uninfected rats [98]. While some
infected rats showed a strong aversion to areas with cat odor,
a proportion of infected rats showed a potentially sexual
attraction to cat-treated areas [93, 99].
The behavioral manipulation hypothesis postulates that a
parasite will specifically manipulate host behaviors essential
for enhancing its own success [14, 100]. However, the
neural circuits involved in learned fear, anxiety, and innate
fear overlap to a great extent, suggesting that the parasite
may disrupt all of these nonspecifically [95]. One group
has reported that the density of cysts in the medial and
basolateral amygdala is almost double that in other structures
such as hippocampus, olfactory bulbs, and prefrontal cortex
[95]. The amygdala performs a primary role in the processing
of memory and emotional reactions, such as fear. This
may be the reason why infected mice show a nonwildtype
attraction to feline odor and/or have modified fear, or sexual
arousal responses. Hence, in this context, the behavioral
manipulation hypothesis would support the capacity of the
parasite to ameliorate innate feline fear, and possibly replace
it by a novel or feline attraction, while appearing to leave
other domains unchanged [101]. To date, however, there is
no known mechanism coordinating infected regions with
changes in behavior.
To the degree that these can be measured, nonmemory-
related cognitive functions, anxiety, and social behavior in
infected mice are unchanged when compared to controls;
yet, they experience profound and widespread brain pathol-
ogy, motor coordination, and sensory deficits [102]. These
changes could be due, in part, to hyperactive MMP proteol-
ysis [103], and/or the creation of novel brain structures [65],
as discussed above. It has been proposed that CNS modifi-
cation following T. gondii infection may behaviorally affect
human hosts, as well [96]. There have been published cor-
relations between latent Toxoplasma infections and human
behavioral changes such as: slower reactions, lower rule con-
sciousness, decreased novelty seeking behavior and greater
jealousy in men, and promiscuity and greater conscientious-
ness in women, as reviewed in [96]. Toxoplasma gondii can
increase the dopamine levels in rodents [104]; this may be
due to the inflammatory release of dopamine by increasing
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cytokines such as interleukin-2, or potentially by direct
parasite production. Many of the neurobehavioral symptoms
that are postulated to be due to toxoplasmosis correlate to the
general function of dopamine in the human brain.
6. Toxoplasma-Associated Psychiatric Sequelae
The dopamine imbalance between the mesolimbic and the
mesocortical regions in the brain is suspected to play a role
in the development of schizophrenia. This may permit a
relationship between schizophrenia and toxoplasmosis [96].
Schizophrenia is one of the most prevalent and severe
psychiatric syndromes.With onset often in young adulthood,
schizophrenia is characterized by impairment in thought
processing, perception, cognition, mood, and psychomotor
behavior [15]. There is a growing interest in the role of
parasites in the causation of psychiatric disorders, in addition
to personality changes, and risk-taking behavior. Of note,
drugs that have antipsychotic and mood stabilizing proper-
ties (which are used in the treatment of schizophrenia and
other psychiatric disorders) may be augmented through their
inhibitory impact upon T. gondii in infected individuals [94].
An example of this is the antipsychotic haloperidol and the
mood stabilizer valproic acid, which most effectively inhibit
Toxoplasma growth in vitro, although not in vivo [105].
To date, no causal link has been demonstrated, but
correlative data is abundant. For example, 185 noninebriated
automobile drivers in Turkey involved in a vehicular accident
within a 6-month window were evaluated for toxoplasmosis.
The cohort of drivers involved in accidents was substan-
tially more likely to have T. gondii infection compared to
the control (nonaccident) group: 33% versus 8.6% sero-
positive, respectively [106]. A number of studies have asses-
sed seropositivity to Toxoplasma gondii in individuals with
schizophrenia and other forms of severe psychiatric dis-
orders, with inconsistent correlative results [107–109]. In
addition, Toxoplasma gondii encephalitis may manifest with
symptoms similar to those of schizophrenia and other psy-
chiatric disorders [110]. There have been a high number
of cases with symptoms that included delusions, thought
disorder, and auditory hallucinations in patients with AIDS
and toxoplasmic encephalitis [15, 110].
Toxoplasma gondii infection has also been associated with
obsessive-compulsive disorder in humans [15]. Men had
“lower superego strengths (rule consciousness) and higher
vigilance” as well as being “more expedient, suspicious and
jealous.” These factors are associated with substance abuse,
anxiety, and personality disorders. Women showed almost
the opposite behavior: with higher superego strength and
factors that suggested warmth, conscientiousness, and moral
adherence. But both men and women were found to have
more apprehension compared with uninfected controls [15,
96]. According to Flegr, differences in the level of testosterone
may be another reason for these observed differences [96].
High testosterone individuals may be more susceptible to
Toxoplasma infection via a less robust immune response,
or observed behavioral changes could be the result of the
parasite inducing testosterone availability in order to further
impair the cellular immunity of the host. In a small study,
seropositive men were found to have higher concentrations
of testosterone than uninfected men; however, it is unknown
whether high testosterone predisposes individuals to infec-
tion behaviorally or biologically, or whether the parasite
indirectly drives testosterone levels. In an ongoing high-
throughput cell-based screening study, overexpression of
17α-hydroxylase in human cells substantially increased the in
vitro rate of Toxoplasma growth, while the inhibition of this
transcript via siRNA decreased intracellular growth (Davis
PH, manuscript in preparation). 17α-hydroxylase is a key
metabolic enzyme responsible for converting cholesterol-like
molecules into androgen precursors, such as testosterone.
This finding suggests that testosterone-like sterols may
directly benefit the growth of the parasite.
7. Future Directions
Due to the growing possibility that T. gondii infection can
alter host behavior, there may be a renewed push for antipar-
asitic agents, as chronic Toxoplasma gondii is untreatable.
Agent development may be difficult, however, due to the
need for drugs to penetrate the blood-brain barrier, as well
as the parasite cyst wall [111]. Moreover, even if the parasites
could be removed from the neurons without creating addi-
tional tissue destruction, preexisting tissue pathology may
preclude resolution of possible behavior-related sequelae.
Recently, a study identified several compounds capable of
inhibiting T. gondii tachyzoites in vitro, in addition to P.
falciparum [112], and some of these compounds are being
investigated for their antibradyzoite properties (Davis PH,
manuscript in preparation).
In addition, the growing understanding of the complex
immunoregulatory processes surrounding parasite infection
may aid possible vaccine development [113]. However, Table
1 indicates the paucity of information on the interplay bet-
ween the immune system and the bradyzoite stage, which
may be a valuable avenue for future exploration. Future
work may also be directed at delineating the process of par-
asite penetration through the blood brain barrier, as well
as a deeper understanding of the molecular events in T cell
control of infection. Much like the contributions of electron
microscopy illuminated our understanding of apicomplexan
organisms [114], so too does advanced imaging, such as bio-
luminescence and two-photon imaging, promise to provide
greater details and real-time information on the workings of
this parasite and its interactions with the host [65, 89, 115–
119].Moreover, the precise role of antigens and host immune
cells promises to be robustly detailed with tetramer-based
molecular tools [61]. Finally, host modification, such that
siRNA and overexpression of host genes, may illuminate crit-
ical cellular factors required for the parasite’s lifecycle [120].
Hi-throughput cell-based screening promises to hasten this
understanding considerably.
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